Role of Botulinum toxin Injection in patients with keloid and hypertrophic scar in reducing the scar size

A prospective study on assessment of efficacy of Intralesional Botulinum toxin type A injection in keloid and hypertrophic scar - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/073901

Enrollment

Registered

2024-09-13

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L910- Hypertrophic scar

Interventions

Intervention1: Intralesional Botulinum toxin injection Type A: Patients with keloid and hypertrophic scar will be treated with Intralesional injection of Botulinum toxin type A. The dose will be adjus

Eligibility

Inclusion criteria

Inclusion criteria: Age: 18 to 65 years Sex: male and female Patients willing for consent, study and follow up regularly Patients with untreated Keloid and Hypertrophic scar.

Exclusion criteria

Exclusion criteria: Age less than 18 years and more than 65 years Pregnancy Lactation Local infection Patients on retinoids or steroids Severe systemic disease Pre existing neuromuscular or cardiovascular diseases Patients not willing for consent,study or follow up HIV/Hepatitis

Design outcomes

Primary

Measure	Time frame
Reduction in the size of the lesionTimepoint: Every month for 6 months	—

Secondary

Measure	Time frame
Reduction in symptoms like itching and painTimepoint: Every month for 6 months	—

Countries

India

Contacts

Public ContactDr Swathi T

The Tamilnadu Dr.M.G.R Medical University, Chennai.

buskibuski@gmail.com9940429206

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026